X

Drug Profile

Research programme: vascular endothelial growth factor b - PhiloGene

Alternative Names: BiCentis; BiVastin; VEGFb

Latest Information Update: 15 Apr 2019

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Bristol
Developer Alcon; PhiloGene
Class Cytokines
Mechanism of Action Vascular endothelial growth factor receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Malignant melanoma
New Molecular Entity No

Highest Development Phases

No development reported Cancer; Retinal disorders

Most Recent Events

09 Apr 2019 Novartis completed the spin-off of Alcon
26 Aug 2010 Alcon has been acquired by Novartis
23 Jul 2009 Vascular endothelial growth factor b licensed to Alcon

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com